<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000301627">
  <TermName>tariquidar</TermName>
  <TermPronunciation>(tar-IH-kwih-dar)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>A substance that is being studied in the treatment of cancer. It may help tumor cells respond again to drugs they have become resistant (unable to respond) to. Tariquidar is a type of multidrug resistance inhibitor and a type of P-glycoprotein antagonist. Also called XR9576.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000709870" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;tariquidar&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000709869" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;tariquidar&quot;" language="es" id="_4"/>
  <SpanishTermName>tariquidar</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Sustancia en estudio para el tratamiento del cáncer, que en ocasiones ayuda a que las células tumorales respondan nuevamente a los medicamentos a los que se han vuelto resistentes (incapaces de responder). El tariquidar es un tipo de antagonista de la glucoproteína-P y un inhibidor de la resistencia a múltiples medicamentos. También se llama XR9576.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2003-04-23</DateFirstPublished>
  <DateLastModified>2008-07-22</DateLastModified>
</GlossaryTerm>
